Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ... New England Journal of Medicine 377 (5), 454-464, 2017 | 2174 | 2017 |
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis … C Thiede, C Steudel, B Mohr, M Schaich, U Schäkel, U Platzbecker, ... Blood, The Journal of the American Society of Hematology 99 (12), 4326-4335, 2002 | 2142 | 2002 |
Mesenchymal stem cells can be differentiated into endothelial cells in vitro J Oswald, S Boxberger, B Jørgensen, S Feldmann, G Ehninger, ... Stem cells 22 (3), 377-384, 2004 | 1840 | 2004 |
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ... New England Journal of Medicine 369 (2), 111-121, 2013 | 1673* | 2013 |
Peripheral-blood stem cells versus bone marrow from unrelated donors C Anasetti, BR Logan, SJ Lee, EK Waller, DJ Weisdorf, JR Wingard, ... New England Journal of Medicine 367 (16), 1487-1496, 2012 | 1008 | 2012 |
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML) C Thiede, S Koch, E Creutzig, C Steudel, T Illmer, M Schaich, G Ehninger, ... Blood 107 (10), 4011-4020, 2006 | 977 | 2006 |
Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and … T Fischer, RM Stone, DJ DeAngelo, I Galinsky, E Estey, C Lanza, E Fox, ... Journal of clinical oncology 28 (28), 4339, 2010 | 596 | 2010 |
Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk … C Schmid, M Labopin, A Nagler, M Bornhäuser, J Finke, A Fassas, ... Journal of clinical oncology 25 (31), 4938-4945, 2007 | 559 | 2007 |
Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation H Einsele, G Ehninger, H Hebart, KM Wittkowski, U Schuler, G Jahn, ... | 542 | 1995 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2 … C Röllig, H Serve, A Hüttmann, R Noppeney, C Müller-Tidow, U Krug, ... The lancet oncology 16 (16), 1691-1699, 2015 | 449 | 2015 |
Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial U Platzbecker, M Wermke, J Radke, U Oelschlaegel, F Seltmann, A Kiani, ... Leukemia 26 (3), 381-389, 2012 | 444 | 2012 |
Individual patient data–based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia … RF Schlenk, A Benner, J Krauter, T Buchner, C Sauerland, G Ehninger, ... Journal of Clinical Oncology 22 (18), 3741-3750, 2004 | 444 | 2004 |
Cure of Helicobacter pylori Infection and Duration of Remission of Low-Grade Gastric Mucosa-Associated Lymphoid Tissue Lymphoma A Neubauer, C Thiede, B Alpen, M Ritter, B Neubauer, G Ehninger, ... Journal of the National Cancer Institute 89 (18), 1350-1355, 1997 | 417 | 1997 |
Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation … A Burchert, G Bug, LV Fritz, J Finke, M Stelljes, C Röllig, E Wollmer, ... Journal of Clinical Oncology 38 (26), 2993-3002, 2020 | 413 | 2020 |
Acute myeloid leukaemia A Khwaja, M Bjorkholm, RE Gale, RL Levine, CT Jordan, G Ehninger, ... Nature reviews Disease primers 2 (1), 1-22, 2016 | 401 | 2016 |
Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non–high-risk acute promyelocytic leukemia: final results of the … U Platzbecker, G Avvisati, L Cicconi, C Thiede, F Paoloni, M Vignetti, ... Journal of Clinical Oncology 35 (6), 605-612, 2017 | 400 | 2017 |
P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate T Illmer, M Schaich, U Platzbecker, J Freiberg-Richter, U Oelschlägel, ... Leukemia 18 (3), 401-408, 2004 | 399 | 2004 |
Rapamycin extends murine lifespan but has limited effects on aging F Neff, D Flores-Dominguez, DP Ryan, M Horsch, S Schröder, T Adler, ... The Journal of clinical investigation 123 (8), 3272-3291, 2013 | 396 | 2013 |
Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation RF Chemaly, AJ Ullmann, S Stoelben, MP Richard, M Bornhäuser, ... New England Journal of Medicine 370 (19), 1781-1789, 2014 | 394 | 2014 |
Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium M Von Bonin, F Stölzel, A Goedecke, K Richter, N Wuschek, K Hölig, ... Bone marrow transplantation 43 (3), 245-251, 2009 | 388 | 2009 |